Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Chlorotoxin suppresses melanoma vasculogenic mimicry via LINC01235/miR-128-3p/YY1/ VEGFR2/NRP1 axis.

Created on 12 Jul 2026

Authors

Xinxin Zhou, Zhaoliang Li, Baicheng Zhu, Lu Zhang, Aodan Yang, Ke Zhu, Chao Li, Shengzhi Wang, Teng Ma

Published in

iScience. Volume 29. Issue 7. Pages 116543. Jul 17, 2026. Epub Jul 06, 2026.

Abstract

Vasculogenic mimicry (VM), a process of vascular-like channel formation for nutrient acquisition, drives melanoma metastasis and poor prognosis. We demonstrate that Chlorotoxin (CTX) effectively targets VM in melanoma. In A375 and A2058 cells, CTX dose-dependently inhibits proliferation with IC50 values of 1.0 and 0.8 μM, respectively. Furthermore, sub-lethal CTX (0.4 μM) impairs cell migration and VM tube formation while downregulating VM regulators VEGFR2 and NRP1. Mechanistically, CTX suppresses the long non-coding RNA LINC01235, a competing endogenous RNA that sponges miR-128-3p. CTX-induced downregulation of LINC01235 frees miR-128-3p to target and suppress the transcription factor YY1. This reduction in YY1 diminishes its binding to the VEGFR2 promoter, ultimately decreasing VEGFR2 and NRP1 transcription. Rescue assays confirm that LINC01235 overexpression restores VM capacity. By defining the LINC01235/miR-128-3p/YY1/VEGFR2/NRP1 signaling axis disrupted by CTX, these findings establish the mechanistic basis for CTX as a promising therapeutic agent against aggressive, VM-competent melanoma.

PMID:
42436998
Bibliographic data and abstract were imported from PubMed on 12 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement